Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907655" target="_blank" >RIV/00216208:11120/13:43907655 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/13:N0000004

Výsledek na webu

<a href="http://dx.doi.org/10.1111/joic.12051" target="_blank" >http://dx.doi.org/10.1111/joic.12051</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/joic.12051" target="_blank" >10.1111/joic.12051</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study

Popis výsledku v původním jazyce

We evaluated the safety and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in real-world clinical practice through 3 years. A randomized comparison of the R-ZES and the XIENCE V everolimus-eluting stent showed no difference in any outcomes through 3-year follow-up in high-volume academic centers. RESOLUTE International is a confirmatory trial designed to evaluate the R-ZES in real-world clinical practice. RESOLUTE International is a single arm, observational trial that enrolled 2,349 patients from 88 centers with only a few inclusion and exclusion criteria. The primary end-point was the composite of cardiac death and target vessel myocardial infarction (TV-MI) at 1 year. Secondary end-points include target lesion failure (TLF), targetvessel revascularization (TVR), and their components, and stent thrombosis (ST). At 3 years 97.2% of patients completed clinical follow-up. The mean age was 63.411.2 years, 77.8% were male, and 30.4% had diabetes. The average number of st

Název v anglickém jazyce

Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study

Popis výsledku anglicky

We evaluated the safety and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in real-world clinical practice through 3 years. A randomized comparison of the R-ZES and the XIENCE V everolimus-eluting stent showed no difference in any outcomes through 3-year follow-up in high-volume academic centers. RESOLUTE International is a confirmatory trial designed to evaluate the R-ZES in real-world clinical practice. RESOLUTE International is a single arm, observational trial that enrolled 2,349 patients from 88 centers with only a few inclusion and exclusion criteria. The primary end-point was the composite of cardiac death and target vessel myocardial infarction (TV-MI) at 1 year. Secondary end-points include target lesion failure (TLF), targetvessel revascularization (TVR), and their components, and stent thrombosis (ST). At 3 years 97.2% of patients completed clinical follow-up. The mean age was 63.411.2 years, 77.8% were male, and 30.4% had diabetes. The average number of st

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Interventional Cardiology

ISSN

0896-4327

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

515-523

Kód UT WoS článku

000325478600011

EID výsledku v databázi Scopus

—